Get the Stockscreener App
1.50
5.06%
-0.08
Pre-market:
1.54
0.04
+2.67%
Palisade Bio Inc stock is traded at $1.50, with a volume of 5.76M.
It is down -5.06% in the last 24 hours and down -28.57% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.58
Open:
$1.56
24h Volume:
5.76M
Relative Volume:
1.14
Market Cap:
$223.80M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1072
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-6.83%
1M Performance:
-28.57%
6M Performance:
+47.06%
1Y Performance:
+12.78%
1-Day Range:
$1.48
$1.58
1-Week Range:
$1.45
$1.675
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.50 | 235.74M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Palisade Bio leaders set for virtual Oppenheimer healthcare conference slot - stocktitan.net
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - The Manila Times
Palisade Bio appoints two IBD experts to clinical advisory board - Investing.com
Two IBD leaders join Palisade Bio push on PALI-2108 for colitis and Crohn's - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat
Published on: 2026-01-19 10:30:24 - baoquankhu1.vn
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com South Africa
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com India
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - Улправда
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 - The Manila Times
Palisade Bio Announces Strategic Equity Investment from the - GlobeNewswire
Crohn’s & Colitis Foundation backs new gut-targeted drug for severe IBD - stocktitan.net
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Palisade Bio, Inc. (NASDAQ:PALI) Receives $20.50 Average Price Target from Analysts - Defense World
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
2.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):